Bleomycin (CED0001279)

Record Information

Version

1.0

Creation Date

2009-07-21 20:26:29 UTC

Update Date

2026-05-14 16:25:13 UTC

SynCED ID

CED0001279

Secondary Accession Numbers

CHEM002161
T3D2738

Identification

Common Name

Bleomycin

Class

Small Molecule

Description

Bleomycin belongs to the hybrid peptides, a subclass of peptidomimetics within the organic compounds. With an average molecular weight of 1,416 g/mol, Bleomycin is a heavy molecule. This exogenous solid has the chemical formula C55H84N17O21S3 and is classified as an organic acid and derivative. It functions as a metabolite and is utilized as an antineoplastic agent. Bleomycin is used in the treatment of cancer (PMC6375222 , PMC6395624 ) and Kaposi's sarcoma (PMC1492602 ). The compound is found in healthcare, pharmaceuticals, and veterinary products. Recorded exposure routes include intra-arterial, intracavitary, intramuscular, intrapleural, intravenous, and subcutaneous administration, with literature support for inhalation (PMC13296829 , PMC5137940 ). Its protein targets include DNA ligase 3 (LIG3), Transient receptor potential cation channel subfamily A member 1 (TRPA1), and DNA ligase 1 (LIG1). Regarding the latter, available evidence indicates the main mode of action is the inhibition of DNA synthesis, with some evidence of lesser inhibition of RNA and protein synthesis. Bleomycin is associated with several health effects. It is linked to an increase in inflammation (PMC2787721 ) and pneumonitis (PMC2787721 ), as well as scleroderma (PMC2995912 ) and melanoma (PMC10137892 ). Additionally, it is associated with a decrease in pulmonary fibrosis (PMC2787721 , PMC5677010 ).

Contaminant Type

Amide
Amine
Antibiotic, Antineoplastic
Antimetabolite
Drug
Ester
Lachrymator
Metabolite
Organic Compound
Synthetic Compound

Chemical Structure

MOL SDF PDB SMILES InChI

Synonyms

Value	Source
Bleocin	HMDB
Bleomicin	HMDB
Bleomycin a2	HMDB
Bleomycin sulfate	HMDB
Bleomycin sulphate	HMDB
BLM	HMDB
Almirall brand OF bleomycin sulfate	HMDB
Bleo cell	HMDB
Bleo-cell	HMDB
BLEOcell	HMDB
Bellon brand OF bleomycin sulfate	HMDB
Bellon, bléomycine	HMDB
Blanoxan	HMDB
Blenoxane	HMDB
Bleolem	HMDB
Bleomicina	HMDB
Bleomycin a(2)	HMDB
Bleomycin b(2)	HMDB
Bleomycin b2	HMDB
Bleomycins	HMDB
Bleomycinum mack	HMDB
Bléomycine bellon	HMDB
Bristol myers squibb brand OF bleomycin sulfate	HMDB
Bristol-myers squibb brand OF bleomycin sulfate	HMDB
Bull brand OF bleomycin sulfate	HMDB
Lemery brand OF bleomycin sulfate	HMDB
Lundbeck brand OF bleomycin sulfate	HMDB
Mack brand OF bleomycin sulfate	HMDB
Mack, bleomycinum	HMDB
Sulfate, bleomycin	HMDB
Cell pharm brand OF bleomycin sulfate	HMDB
Bleomycin	MeSH

Chemical Formula

C₅₅H₈₄N₁₇O₂₁S₃

Average Molecular Mass

1415.552 g/mol

Monoisotopic Mass

1414.519 g/mol

CAS Registry Number

11056-06-7

IUPAC Name

(3-{[2-(2-{2-[(2S,3R)-2-[(2S,3S,4R)-4-[(2S,3R)-2-({6-amino-2-[(1S)-1-{[(2S)-2-amino-2-carbamoylethyl]amino}-2-carbamoylethyl]-5-methylpyrimidin-4-yl}formamido)-3-[(3-{[4-(carbamoyloxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]-3-(1H-imidazol-5-yl)propanamido]-3-hydroxy-2-methylpentanamido]-3-hydroxybutanamido]ethyl}-1,3-thiazol-4-yl)-1,3-thiazol-4-yl]formamido}propyl)dimethylsulfanium

Traditional Name

bleomycin

SMILES

C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C

InChI Identifier

InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1

InChI Key

OYVAGSVQBOHSSS-WXFSZRTFSA-O

Chemical Taxonomy

Description

Belongs to the class of organic compounds known as hybrid glycopeptides. Hybrid glycopeptides are compounds containing a carbohydrate component linked to a hybrid peptide component.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Peptidomimetics

Sub Class

Hybrid peptides

Direct Parent

Hybrid glycopeptides

Alternative Parents

Substituents

Hybrid glycopeptide
Histidine or derivatives
Fatty acyl glycoside of mono- or disaccharide
Fatty acyl glycoside
N-acyl-alpha amino acid or derivatives
Gamma amino acid or derivatives
Alpha-amino acid amide
Beta amino acid or derivatives
O-glycosyl compound
Glycosyl compound
Disaccharide
N-substituted-alpha-amino acid
Alpha-amino acid or derivatives
Pyrimidine-6-carboxylic acid or derivatives
2-heteroaryl carboxamide
Thiazolecarboxamide
Thiazolecarboxylic acid or derivatives
Aralkylamine
2,4-disubstituted 1,3-thiazole
Aminopyrimidine
Fatty amide
Fatty acyl
N-acyl-amine
Imidolactam
Oxane
Pyrimidine
Azole
Carbamic acid ester
Heteroaromatic compound
Thiazole
Imidazole
Secondary alcohol
Carboxamide group
Carbonic acid derivative
Amino acid or derivatives
Secondary carboxylic acid amide
Primary carboxylic acid amide
Organoheterocyclic compound
Secondary aliphatic amine
Oxacycle
Acetal
Carboxylic acid derivative
Azacycle
Secondary amine
Organic nitrogen compound
Organic oxygen compound
Primary aliphatic amine
Organonitrogen compound
Organooxygen compound
Carbonyl group
Organosulfur compound
Primary alcohol
Primary amine
Amine
Hydrocarbon derivative
Organic oxide
Organopnictogen compound
Alcohol
Organic cation
Aromatic heteromonocyclic compound

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

Non-ribosomal peptide/polyketide hybrids (LMPK14000006 )

Biological Properties

Status

Detected and Not Quantified

Origin

Exogenous

Cellular Locations

Cytoplasm
Membrane

Biofluid Locations

Not Available

Tissue Locations

Not Available

Applications

antineoplastic agent

Biological Roles

mutagen (PMC2896875 )?A chemical substance that alters the genetic material of an organism, and increases the frequency of mutations above the naturally-occuring rate
poison (PMC13296829 )?A chemical substance, naturally occurring or synthetic, that is harmful to an organism exposed to it in sufficient amounts
genotoxin (PMC8448691 )?A chemical substance that alters the genetic material of an organism,directly or indirectly
antimicrobial agent (PMC9612312 , PMC7247559 )?
metabolite ?A chemical produced during metabolism process, as an intermediate or end-product
toxin (PMC3670679 )?A chemical substance naturally produced by an organism and poisonous to other organisms
antineoplastic agent (PMC5137940 , PMC5137940 )?
vancomycin (PMC12732419 , PMC8199173 )?

Chemical Roles

Not Available

Organoleptic Effects

Not Available

Physical Properties

State

Solid

Appearance

White powder.

Experimental Properties

Property	Value
Melting Point	71°C
Boiling Point	Not Available
Solubility	Soluble

Predicted Properties

Property	Value	Source
Water Solubility	0.028 g/L	ALOGPS
logP	-0.52	ALOGPS
logP	-9.7	ChemAxon
logS	-4.7	ALOGPS
pKa (Strongest Acidic)	11.34	ChemAxon
pKa (Strongest Basic)	7.67	ChemAxon
Physiological Charge	2	ChemAxon
Hydrogen Acceptor Count	28	ChemAxon
Hydrogen Donor Count	20	ChemAxon
Polar Surface Area	627.07 Å²	ChemAxon
Rotatable Bond Count	36	ChemAxon
Refractivity	344.16 m³·mol⁻¹	ChemAxon
Polarizability	142.03 Å³	ChemAxon
Number of Rings	6	ChemAxon
Bioavailability	No	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Spectra

Spectrum Type	Description	Splash Key	Deposition Date	View
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0002-5519000000-a9e7e590fae8c464ce36	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-05fr-5918000000-5ca154887c83cf983142	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-05fr-5925010000-dfb06a8f5285854a7878	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-052b-2009100001-5547a667899fb11dad81	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0bt9-0009400042-5683bd6165401e99baa9	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0cdl-2129410101-b208548fe3870fadd6fe	Not Available	View Spectrum
1D NMR	¹H NMR Spectrum (1D, D₂O, predicted)	Not Available	Not Available	View Spectrum
1D NMR	¹³C NMR Spectrum (1D, D₂O, predicted)	Not Available	Not Available	View Spectrum

Toxicity Profile

Toxicity Values

Not Available

Toxicity / Toxin Class

Not Available

Mechanism of Toxicity

It has been suggested that bleomycin induces sensitivity to oxygen toxicity and recent studies support the role of the proinflammatory cytokines IL-18 and IL-1beta in the mechanism of bleomycin-induced lung injury. (Wikipedia) In primary pulmonary endothelial cells, bleomycin initiates apoptosis via the extrinsic pathway (2). In relation to bleomycin-induced scleroderma, bleomycin exerts various effects on skin-constituted cells such as fibroblasts, keratinocytes, and endothelial cells, as well as immunocytes. Bleomycin upregulates gene expression of ECM proteins as well as fibrogenic cytokines such as TGF-β and CTGF in cultured human skin fibroblasts. Also, in vitro studies showed a dose-dependent stimulation of endothelial cell secretion of collagen synthesis by bleomycin, which was inhibited by the anti-TGF-β antibody. (3).

Carcinogenicity (IARC Classification)

2B, possibly carcinogenic to humans. (5)

Minimum Risk Level

Not Available

Symptoms

Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction.

Treatment

Not Available

Health Effects

Health Effect	Relationship	Direction	Description	Reference
lung cancer	Not Available	Not Available	A respiratory system cancer that is located in the lung. (DO)	PMC11207985
inflammation	Associated With?	increase	Not Available	PMC2787721
cancer	Not Available	Not Available	Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. There are over 100 types of cancers affect humans. The risk of developing certain cancers can be reduced by not smoking, maintaining a healthy weight, not drinking too much alcohol, eating plenty of vegetables, fruits and whole grains, vaccination against certain infectious diseases, not eating too much processed and red meat and avoiding too much sunlight exposure. Cancer is often treated with some combination of radiation therapy, surgery, chemotherapy and targeted therapy. The majority of cancers, some 90–95% of cases, are due to genetic mutations from environmental and lifestyle factors. The remaining 5–10% are due to inherited genetics.	PMC6375222 , PMC6395624
melanoma	Associated With?	Not Available	A cell type cancer that has material basis in abnormally proliferating cells derives from melanocytes which are found in skin, the bowel and the eye. (DO)	PMC10137892
necrosis	Associated With?	Not Available	A disorder characterized as a form of cell injury which results in the premature death of cells in living tissue by autolysis.	PMC7149505
liver disease	Associated With?	Not Available	A disorder characterized by any variety of factors leading to damage to the liver.	PMC12403781
testicular cancer	Not Available	Not Available	A male reproductive system cancer that is located in the testicles. (DO)	PMC11902694
testicular cancer	Has Therapeutic Effect On	Not Available	A male reproductive system cancer that is located in the testicles. (DO)	PMC13381201
pulmonary fibrosis	Associated With?	decrease	Not Available	PMC2787721 , PMC2787721
pulmonary fibrosis	Associated With?	Not Available	Not Available	PMC6536957 , PMC6537011
pulmonary fibrosis	Associated With?	increase	Not Available	PMC12775725 , PMC11207985
Kaposi's sarcoma	Not Available	Not Available	Not Available	PMC1492602
idiopathic pulmonary fibrosis	Associated With?	Not Available	Not Available	PMC10626779
non-Hodgkin lymphoma	Not Available	Not Available	Not Available	PMC7123643
scleroderma	Associated With?	Not Available	Not Available	PMC2995912
pneumonitis	Associated With?	increase	Not Available	PMC2787721
pneumonitis	Associated With?	Not Available	Not Available	PMC3670679
squamous cell carcinoma	Not Available	Not Available	A carcinoma that derives from squamous epithelial cells. (DO)	PMC12671112
hepatic fibrosis	Associated With?	Not Available	Not Available	PMC11902694
carcinoma	Not Available	Not Available	Not Available	PMC2993000
embryonal carcinoma	Not Available	Not Available	Not Available	PMC4718299
head and neck squamous cell carcinoma	Not Available	Not Available	Not Available	PMC10724599
bronchiolitis obliterans	Associated With?	Not Available	Not Available	PMC7123643
Abnormality of mitochondrial metabolism	Associated With?	decrease	Not Available	PMC5948269
Oxidative Stress	Associated With?	Not Available	Not Available	PMC3914546
Oxidative Stress	Associated With?	increase	Not Available	PMC10724599
DNA Damage	Associated With?	decrease	Not Available	PMC8533760
DNA Damage	Associated With?	Not Available	Not Available	PMC6268533 , PMC7247559
Fibrosis	Associated With?	Not Available	Not Available	PMC2787721 , PMC3670679
acute lung injury	Associated With?	Not Available	Not Available	PMC9836372
Lung Injury	Associated With?	Not Available	Not Available	PMC8545719
Death	Associated With?	increase	Not Available	PMC7123643
DNA Breaks, Double-Stranded	Associated With?	Not Available	Not Available	PMC3589417
cutaneous sclerosis	Associated With?	Not Available	Not Available	PMC11180720
Hodgkin's lymphoma	Not Available	Not Available	Not Available	PMC12671112 , PMC7123643
Hodgkin's lymphoma	Has Therapeutic Effect On	Not Available	Not Available	PMC13381201
Anaphylactic shock	Associated With?	Not Available	Not Available	PMC7123643
Teratoma	Not Available	Not Available	Not Available	PMC12821418
localized scleroderma	Associated With?	Not Available	Not Available	PMC11204138
Interstitial pneumonitis	Associated With?	Not Available	Not Available	PMC7123643
adamantinous craniopharyngioma	Not Available	Not Available	Not Available	PMC13238868
cryptogenic organizing pneumonia	Associated With?	Not Available	Not Available	PMC7123643

Exposure Sources

Source ID	Source	Sector	Reference
CEDs000358	Antineoplastic agents?Antineoplastic agents are a class of synthetic chemicals used primarily in the treatment of cancer.	Healthcare, pharmaceuticals & veterinary products	Not Available
CEDs000468	Industrial wastewater?Industrial wastewater is a byproduct generated during various manufacturing and processing activities, which often contains a complex mixture of organic and inorganic synthetic chemicals.	Wastewater, sanitation & biosolids	PMC11238013
CEDs000579	Manufacture Of Iron Or Steel?The manufacture of iron or steel involves various processes, including smelting, refining, and alloying, which can result in the release of synthetic chemicals and contaminants.	Industrial manufacturing & chemical processing	PubChem
CEDs000685	Ceramics?Ceramics can be a source of synthetic chemical contamination through various additives and processing agents used in their production.	Building & Construction	PubChem
CEDs000696	Nanotechnology?Nanotechnology involves the manipulation of materials at the molecular or atomic level, typically within the range of 1 to 100 nanometers.	Industrial manufacturing & chemical processing	PubChem
CEDs000740	Paper?Paper production involves the processing of wood fibers and the use of various chemicals, which can lead to synthetic chemical contamination.	Paper, pulp & fiber products	PubChem
CEDs02255	Water	Aquatic systems & sediments	PMC10797042
CEDs02270	River	Aquatic systems & sediments	PMC6172301

Pathways

1 pathwayPathway Source: PathBank

Bleomycin Drug Metabolism Action Pathway

Targets

Structure	Protein	UniProt ID	Organism	Relationship	Details
Click to view 3D structure	Rhombotin-2	P25791	Humans	Predicted (SEA)	Prediction Confidence Score 0.202 Applicability Domain 0.202 Low confidence Statistical Significance 0.0267 Supporting Reference Compounds 1 E-value 208.247
Click to view 3D structure	Endo-beta-N-acetylglucosaminidase	Q9ZB22	Arthrobacter protophormiae	Predicted (SEA)	Prediction Confidence Score 0.193 Applicability Domain 0.193 Low confidence Statistical Significance 0.0021 Supporting Reference Compounds 1 E-value 16.3483
Click to view 3D structure	BTB/POZ domain-containing protein KCTD11	Q693B1	Humans	Predicted (SEA)	Prediction Confidence Score 0.192 Applicability Domain 0.192 Low confidence Statistical Significance 0.0296 Supporting Reference Compounds 1 E-value 230.589
Click to view 3D structure	Caveolin-1	Q03135	Humans	Predicted (SEA)	Prediction Confidence Score 0.187 Applicability Domain 0.187 Low confidence Statistical Significance 0.029 Supporting Reference Compounds 1 E-value 225.996
Click to view 3D structure	N-alpha-acetyltransferase 40	Q86UY6	Humans	Predicted (SEA)	Prediction Confidence Score 0.186 Applicability Domain 0.189 Low confidence Statistical Significance 0.0132 Supporting Reference Compounds 2 E-value 102.917
Click to view 3D structure	IgG receptor FcRn large subunit p51	P55899	Humans	Predicted (SEA)	Prediction Confidence Score 0.185 Applicability Domain 0.185 Low confidence Statistical Significance 0.0339 Supporting Reference Compounds 1 E-value 264.065
Click to view 3D structure	Glucagon-like peptide 2 receptor	Q9Z0W0	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.183 Applicability Domain 0.183 Low confidence Statistical Significance 0.031 Supporting Reference Compounds 1 E-value 241.255
Click to view 3D structure	Histidine--tRNA ligase, cytoplasmic	P12081	Humans	Predicted (SEA)	Prediction Confidence Score 0.182 Applicability Domain 0.182 Low confidence Statistical Significance 0.0099 Supporting Reference Compounds 1 E-value 77.0707
Click to view 3D structure	Neuropeptide Y receptor type 2	P49146	Humans	Predicted (SEA)	Prediction Confidence Score 0.18 Applicability Domain 0.198 Low confidence Statistical Significance 0.4164 Supporting Reference Compounds 57 E-value 3241.49
Click to view 3D structure	Neuropeptide Y receptor type 1	P25929	Humans	Predicted (SEA)	Prediction Confidence Score 0.18 Applicability Domain 0.198 Low confidence Statistical Significance 0.4326 Supporting Reference Compounds 65 E-value 3368.07
Click to view 3D structure	Histone acetyltransferase GCN5	Q245K9	Tetrahymena thermophila (strain SB210)	Predicted (SEA)	Prediction Confidence Score 0.18 Applicability Domain 0.18 Low confidence Statistical Significance 0.019 Supporting Reference Compounds 2 E-value 148.147
Click to view 3D structure	Glucagon-like peptide 1 receptor	P43220	Humans	Predicted (SEA)	Prediction Confidence Score 0.18 Applicability Domain 0.183 Low confidence Statistical Significance 0.5012 Supporting Reference Compounds 67 E-value 3901.57
Click to view 3D structure	Glucagon-like peptide 2 receptor	O95838	Humans	Predicted (SEA)	Prediction Confidence Score 0.177 Applicability Domain 0.183 Low confidence Statistical Significance 0.034 Supporting Reference Compounds 4 E-value 264.765
Click to view 3D structure	Aminoglycoside acetyltransferase	Q70E71	Enterococcus durans	Predicted (SEA)	Prediction Confidence Score 0.175 Applicability Domain 0.175 Low confidence Statistical Significance 0.0066 Supporting Reference Compounds 1 E-value 51.2248
Click to view 3D structure	Kelch-like protein 3	Q9UH77	Humans	Predicted (SEA)	Prediction Confidence Score 0.175 Applicability Domain 0.175 Low confidence Statistical Significance 0.0267 Supporting Reference Compounds 1 E-value 208.013
Click to view 3D structure	Phospho-N-acetylmuramoyl-pentapeptide-transferase	O66465	Aquifex aeolicus (strain VF5)	Predicted (SEA)	Prediction Confidence Score 0.175 Applicability Domain 0.175 Low confidence Statistical Significance 0.0031 Supporting Reference Compounds 1 E-value 24.5225
Click to view 3D structure	Sclerostin	Q99P67	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.175 Applicability Domain 0.175 Low confidence Statistical Significance 0.0357 Supporting Reference Compounds 1 E-value 278.311
Click to view 3D structure	Placenta growth factor	P49764	Mus musculus	Predicted (SEA)	Prediction Confidence Score 0.175 Applicability Domain 0.178 Low confidence Statistical Significance 0.027 Supporting Reference Compounds 2 E-value 210.582
Click to view 3D structure	Phospho-N-acetylmuramoyl-pentapeptide-transferase	P9WMW7	Mycobacterium tuberculosis	Predicted (SEA)	Prediction Confidence Score 0.173 Applicability Domain 0.173 Low confidence Statistical Significance 0.0132 Supporting Reference Compounds 1 E-value 102.527
Click to view 3D structure	Glucagon-like peptide 1 receptor	O35659	Mus musculus	Predicted (SEA)	Prediction Confidence Score 0.172 Applicability Domain 0.175 Low confidence Statistical Significance 0.0384 Supporting Reference Compounds 8 E-value 299.252
Click to view 3D structure	Glypican-3	P51654	Humans	Predicted (SEA)	Prediction Confidence Score 0.172 Applicability Domain 0.172 Low confidence Statistical Significance 0.0296 Supporting Reference Compounds 1 E-value 230.2
Click to view 3D structure	Dickkopf WNT-signaling pathway inhibitor 1	A6I0Z0	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.171 Applicability Domain 0.171 Low confidence Statistical Significance 0.0359 Supporting Reference Compounds 1 E-value 279.557
Click to view 3D structure	Melanocortin receptor 4	P32245	Humans	Predicted (SEA)	Prediction Confidence Score 0.169 Applicability Domain 0.175 Low confidence Statistical Significance 0.6632 Supporting Reference Compounds 96 E-value 5162.73
Click to view 3D structure	Sodium channel protein type 4 subunit alpha	Q9ER60	Mus musculus	Predicted (SEA)	Prediction Confidence Score 0.169 Applicability Domain 0.169 Low confidence Statistical Significance 0.024 Supporting Reference Compounds 1 E-value 186.838
Click to view 3D structure	Delta-type opioid receptor	P41143	Humans	Predicted (SEA)	Prediction Confidence Score 0.169 Applicability Domain 0.175 Low confidence Statistical Significance 0.9174 Supporting Reference Compounds 427 E-value 7141.89
Click to view 3D structure	Bleomycin hydrolase	Q13867	Humans	Known	Not Available
Click to view 3D structure	DNA ligase 1	P18858	Humans	Known	Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis.
Click to view 3D structure	DNA ligase 3	P49916	Humans	Known	Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis.
Click to view 3D structure	Transient receptor potential cation channel subfamily A member 1	O75762	Humans	Known	Not Available

Concentrations

Not Available

External Links

DrugBank ID

DB00290

HMDB ID

HMDB0014435

FooDB ID

Not Available

Phenol Explorer ID

Not Available

KNApSAcK ID

Not Available

BiGG ID

Not Available

BioCyc ID

Not Available

METLIN ID

Not Available

PDB ID

Not Available

Wikipedia Link

Chemspider ID

ChEBI ID

PubChem Compound ID

Kegg Compound ID

YMDB ID

Not Available

ECMDB ID

Not Available

References

Synthesis Reference

Hamao Umezawa, Kenji Maeda, Tomohisa Takita, Yuya Nakayama, Akio Fujii, Nobuyoshi Shimada, Hideo Chimura, “Novel process for producing antibiotics bleomycin.” U.S. Patent USRE0304514, issued October, 1970.

MSDS

Link

General References

Claussen CA, Long EC: Nucleic Acid recognition by metal complexes of bleomycin. Chem Rev. 1999 Sep 8;99(9):2797-816. [PubMed: 11749501]
Mungunsukh O, Griffin AJ, Lee YH, Day RM: Bleomycin induces the extrinsic apoptotic pathway in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2010 May;298(5):L696-703. doi: 10.1152/ajplung.00322.2009. Epub 2010 Feb 12. [PubMed: 20154224]
Yamamoto T, Katayama I: Vascular changes in bleomycin-induced scleroderma. Int J Rheumatol. 2011;2011:270938. doi: 10.1155/2011/270938. Epub 2011 Oct 19. [PubMed: 22028717]
Finch WR, Rodnan GP, Buckingham RB, Prince RK, Winkelstein A: Bleomycin-induced scleroderma. J Rheumatol. 1980 Sep-Oct;7(5):651-9. [PubMed: 6160247]
International Agency for Research on Cancer (2014). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. - http://monographs.iarc.fr/index.php
Drugs.com - http://www.drugs.com/cons/Bleomycin.html

Bleomycin (CED0001279)

Structure for CHEM002161: Bleomycin

Structure